205 related articles for article (PubMed ID: 36845618)
1. Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab.
Diamond BH; Belani N; Masel R; DeCarli K; DiPetrillo T; Hepel JT; Azzoli CG; Khurshid H; Abbas A; Koffer PP
Adv Radiat Oncol; 2023; 8(2):101130. PubMed ID: 36845618
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab.
Gao RW; Day CN; Yu NY; Bush A; Amundson AC; Prodduturvar P; Majeed U; Butts E; Oliver T; Schwecke AJ; Moffett JN; Routman DM; Breen WG; Potter AL; Rivera-Concepcion J; Hoppe BS; Schild SE; Sio TT; Lou Y; Ernani V; Ko S; Olivier KR; Merrell KW; Garces YI; Manochakian R; Harmsen WS; Leventakos K; Owen D
Lung Cancer; 2022 Aug; 170():58-64. PubMed ID: 35716632
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
McCall NS; Janopaul-Naylor JR; McGinnis HS; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal TA; Ramalingam SS; Bradley JD; Higgins KA
Cancer; 2023 Dec; 129(23):3713-3723. PubMed ID: 37354070
[TBL] [Abstract][Full Text] [Related]
4. Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer.
Hassanzadeh C; Sita T; Savoor R; Samson PP; Bradley J; Gentile M; Roach M; Mohindra N; Waqar S; Kruser TJ; Robinson C
J Thorac Dis; 2020 Nov; 12(11):6690-6700. PubMed ID: 33282370
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors.
Bi J; Qian J; Yang D; Sun L; Lin S; Li Y; Xue X; Nie T; Verma V; Han G
Front Immunol; 2021; 12():828858. PubMed ID: 35095930
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
Sakagami M; Inokuchi H; Mukumoto N; Itoyama H; Hamaura N; Yamagishi M; Mukumoto N; Matsuda S; Kabata D; Shibuya K
Radiat Oncol; 2023 May; 18(1):87. PubMed ID: 37217919
[TBL] [Abstract][Full Text] [Related]
7. Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?
Thomas HMT; Hippe DS; Forouzannezhad P; Sasidharan BK; Kinahan PE; Miyaoka RS; Vesselle HJ; Rengan R; Zeng J; Bowen SR
Discov Oncol; 2022 Sep; 13(1):85. PubMed ID: 36048266
[TBL] [Abstract][Full Text] [Related]
8. Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
Miura Y; Mouri A; Kaira K; Yamaguchi O; Shiono A; Hashimoto K; Nishihara F; Shinomiya S; Akagami T; Murayama Y; Abe T; Noda SE; Kato S; Kobayashi K; Kagamu H
Thorac Cancer; 2020 May; 11(5):1280-1287. PubMed ID: 32160383
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer.
Landman Y; Jacobi O; Kurman N; Yariv O; Peretz I; Rotem O; Dudnik E; Zer A; Allen AM
Oncoimmunology; 2021; 10(1):1959979. PubMed ID: 34408921
[TBL] [Abstract][Full Text] [Related]
10. Incidence and dose-volume relationship of radiation pneumonitis after concurrent chemoradiotherapy followed by durvalumab for locally advanced non-small cell lung cancer.
Saito S; Abe T; Kobayashi N; Aoshika T; Ryuno Y; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
Clin Transl Radiat Oncol; 2020 Jul; 23():85-88. PubMed ID: 32529055
[TBL] [Abstract][Full Text] [Related]
11. Ipsilateral lung dose volume parameters predict radiation pneumonitis in addition to classical dose volume parameters in locally advanced NSCLC treated with combined modality therapy.
Agrawal S; Kumar S; Lawrence A; Das MK; Kumar S
South Asian J Cancer; 2014 Jan; 3(1):13-5. PubMed ID: 24665439
[TBL] [Abstract][Full Text] [Related]
12. Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer.
Inoue H; Ono A; Kawabata T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Yasui K; Ogawa H; Onoe T; Endo M; Harada H; Takahashi T
Invest New Drugs; 2020 Oct; 38(5):1612-1617. PubMed ID: 32128667
[TBL] [Abstract][Full Text] [Related]
13. Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation.
Yegya-Raman N; Friedes C; Lee SH; Iocolano M; Duan L; Wang X; Li B; Aggarwal C; Cohen RB; Su W; Doucette A; Levin WP; Cengel KA; DiBardino D; Teo BK; O'Reilly SE; Sun L; Bradley JD; Xiao Y; Langer CJ; Feigenberg SJ
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1445-1454. PubMed ID: 37619788
[TBL] [Abstract][Full Text] [Related]
14. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
Saito G; Oya Y; Taniguchi Y; Kawachi H; Daichi F; Matsumoto H; Iwasawa S; Suzuki H; Niitsu T; Miyauchi E; Yokoi T; Yokoyama T; Uenami T; Sakata Y; Arai D; Okada A; Nagata K; Teraoka S; Kokubo M
Lung Cancer; 2021 Nov; 161():86-93. PubMed ID: 34543942
[TBL] [Abstract][Full Text] [Related]
15. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer.
Altan M; Soto F; Xu T; Wilson N; Franco-Vega MC; Simbaqueba Clavijo CA; Shannon VR; Faiz SA; Gandhi S; Lin SH; Lopez P; Zhong L; Akhmedzhanov F; Godoy MCB; Shroff GS; Wu J; Khawaja F; Kim ST; Naing A; Heymach JV; Daniel-Macdougall C; Liao Z; Sheshadri A
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):630-639. PubMed ID: 37507279
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
Nishimura A; Ono A; Wakuda K; Kawabata T; Yabe M; Miyawaki T; Miyawaki E; Kodama H; Nishioka N; Mamesaya N; Kobayashi H; Omori S; Kenmotsu H; Naito T; Murakami H; Harada H; Takahashi T
Invest New Drugs; 2022 Apr; 40(2):403-410. PubMed ID: 34633575
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study.
Lim CA; Ghosh S; Morrison H; Meyers D; Stukalin I; Kerba M; Hao D; Pabani A
Curr Oncol; 2023 Dec; 30(12):10396-10407. PubMed ID: 38132391
[TBL] [Abstract][Full Text] [Related]
18. Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer.
Kim M; Lee J; Ha B; Lee R; Lee KJ; Suh HS
Radiat Oncol J; 2011 Sep; 29(3):181-90. PubMed ID: 22984669
[TBL] [Abstract][Full Text] [Related]
19. Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy.
Ramella S; Trodella L; Mineo TC; Pompeo E; Stimato G; Gaudino D; Valentini V; Cellini F; Ciresa M; Fiore M; Piermattei A; Russo P; Cesario A; D'Angelillo RM
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):110-5. PubMed ID: 19619955
[TBL] [Abstract][Full Text] [Related]
20. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab.
Liu Y; Zhang Z; Rinsurongkawong W; Gay CM; Le X; Ning MS; Lewis J; Rinsurongkawong V; Lee JJ; Roth J; Swisher S; Gandhi S; Lee PP; Gibbons DL; Vaporciyan AA; Heymach JV; Zhang J; Lin SH
JAMA Netw Open; 2022 Jun; 5(6):e2215589. PubMed ID: 35666500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
